What changed, and where it came from.
We check official sources every day — the Judicial Panel on Multidistrict Litigation, federal courts, the FDA, EPA, and SSA. An editor verifies each change before it appears here or on a campaign page.
- JPMLMonthly pending-case report publishedPending-case counts refreshed on every campaign page with a federal case group, after editor review.View source (opens in a new tab)
- PfizerOxbryta will not return to the U.S. marketStatus stays at Monitoring. There is no consolidated federal case group at this time.View source (opens in a new tab)
- FDAMeningioma added to Depo-Provera warningsFDA approved labeling that adds meningioma to Warnings and Precautions.View source (opens in a new tab)